IL6 and hepatocellular carcinoma: Compared to the control group treated with DMSO, NVP-BEZ235 and IL-6 antibody treatment alone reduced the migration ability of HCC cells, while the inhibitory effect of NVP-BEZ235 and IL-6 antibody cotreatment on the migration ability of HCC cells was more obvious, indicating that IL-6 blockade enhances the inhibitory effect of NVP-BEZ235 on cell migration (Fig. 5A).